Showing posts with label retraction. Show all posts
Showing posts with label retraction. Show all posts

Friday, January 29, 2016

Retractions - One now, perhaps more in the future

We've written before about article retractions and why high-profile journals like NEJM might have the highest retraction indices (figure). Yet, retractions in infection prevention are very infrequent. In fact, the one major retraction we mentioned during 7 years of blogging was not strictly a retraction, but a re-analysis of N-95 vs surgical masks.

Which brings us to a rare retraction in infection prevention, namely this 2014 AJIC study looking at zero fluid displacement intravenous needless connector and CLABSI prevention. As reported this week in Retraction Watch, the study was initially questioned because of a failure to report conflicts of interest but has now been fully retracted by AJIC since an investigation found problems with the "consistency of the statistics over various study periods as well as the methods by which study sites were chosen." Fortunately, since this study was published less than 2-years ago and only cited once, this retractions won't be particularly damaging to the field.

However, with the recent announcement that NIH is providing an additional $100 million for antimicrobial resistance (AMR) along with increases in CDC and industry funding, there are now resources to fund high-impact studies that will appear in high-impact journals. And as if those pressures are not enough, the US Government has been tasked to reduce C. difficile infection by 50%, CRE by 60% and MRSA by 50% by 2020 compared to 2011. With the unprecedented increase in funding combined with difficult to achieve targets, there will be unbelievable pressure to cut corners in study design and analysis and over-promise or over-promote results. This all represents a potential recipe for disaster if our field isn't careful. On the bright side, societies like SHEA have very strict conflict of interest reporting, so we have some checks in place to identify conflicts and bias. Of course, this won't be enough. Be careful out there.

Thursday, April 19, 2012

Manuscript Provenance: Why NEJM has a high retraction rate (and it's not a reason mentioned in the NYT)

A recent high-profile story in the NYT by Carl Zimmer discussed a surge in article retractions since 2000. Over the period 2000 to 2009, retractions have risen by 3300%. (see calcs below) The Time's article draws much of its data and discussion from a pair of editorials published by Ferric Fang and Arturo Casadevall covering "structural reforms" and "methodological and cultural reforms" and a recent news feature in Nature. I highly recommend the two calls for reform from Fang and Casadevall, which cover topics ranging from increased administrative burden to problems with grant review. However, it is hard to make a link from any of these problems and scientific error or misconduct without further research.

For example, much of the discussion falls into the category of "survival of the fittest" with scientists doing everything possible to publish in high-profile journals (e.g. NEJM), which then is supposed to lead to increased grant funding and wealth.  I'm not denying that this could be a factor in scientific fraud, but it's hard to imagine this would increase errors, directly. If you look at the NYT graphic (above), fraud is associated with a minority of all retractions. To provide evidence that a scientists desire for fame is driving the retraction epidemic, Fang and Casadevall, published another editorial that included an analysis linking impact factor of the journal to a retraction index. They found that the higher the impact factor, the higher rate of retraction with NEJM at the top.


Reasons given for the association include higher risk-taking by authors in papers submitted to high-ranking journals and that publications in high-impact journals may just be subject to greater scrutiny (e.g. via social media). These reasons are appealing, although I'm not sure there's a testable hypothesis among them. One testable "systemic aspect of the scientific publication process" that is likely to be associated with both journal rank and retraction (and more likely to be causal) is a manuscript's provenance.

Manuscript Provenance
In the art world, a painting's provenance refers to the chronology of ownership of a specific painting or work.  When I speak of a manuscript's provenance, I mean where it's been submitted and received peer review prior to publication.  As anyone who has submitted a manuscript knows, you almost always submit the paper to a higher-impact journal first and then if not reviewed or accepted, you aim a bit lower.  In fact, there is only one paper we've submitted out of >100, that's gone initially to a lower-ranked journal and then when rejected, was submitted and accepted by a higher-ranked journal.

Thus, manuscripts submitted and accepted at higher-ranked journals are more likely to have been reviewed only once, or received one round of peer review. Yes, I know that some papers go to JAMA then NEJM and some papers are submitted directly to a specialty journal and are reviewed once, but in general, papers published in higher-ranked journals have been through fewer rounds of peer review.  Unfortunately, these data are not easily available, but it's likely this hypothesis can be tested. Nevertheless, I think quantity of peer review is an important predictor of quality of the final product.  It is unlikely that more peer review could detect outright fraud, but most retractions aren't fraud related.

So before we blame the entire system for a few bad apples, there need to be more epidemiological studies as to why this is occurring.  My first suggestion is that we should consider manuscript provenance as a factor and my second suggestion is that journals should pay for peer review, so that it becomes a valued exercise.  Peer review service should also be considered for promotion. Sure the system could be improved in many ways, but it's a stretch from there to finding a causal pathway between a journal's impact factor and a higher retraction index. Oh, and this is all probably because of twitter anyway.


***Retraction Rate Calculation: Using rates of 3/year in 2000 to 180/year in 2009 from the NYT article and given that there's been a 64% increase in PubMed articles  (529,000 in 2000 to 866,000 articles in 2010), this represents an increase from 0.0006% to 0.02%, or a 3300% increase.

Tuesday, December 27, 2011

Two papers linking XMRV and chronic fatigue syndrome retracted

Mike posted on a paper refuting the possible link between XMRV and chronic fatigue syndrome over a year ago.  Now it appears that both the 2009 Science paper and  2010 PNAS paper supporting such a link have been retracted.  The reasons for retraction of each paper appear to be very different.  For example, the story of the Science paper authors' possible image manipulation described by blogger Abbie Smith is pretty fascinating.  A great description of both retractions and related media reports can be found for both the Science and PNAS paper at Retraction Watch.  All of this is very unfortunate for the scientific community and especially the affected patients.

Sources:

Retraction of Lombardi et al., Science 326 (5952) 585-589 in Science 23 December 2011: Vol. 334 no. 6063 p. 1636 

NY Times, David Tuller 12/26/2011

h/t Ivan Oransky at Retraction Watch Blog 12/26/2011

OSHA! OSHA! OSHA!

  In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...